Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LNSR 
LENSAR Inc (LNSR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LNSR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 62.19% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 165.77M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 213153 | Beta 0.62 | 52 Weeks Range 2.67 - 17.31 | Updated Date 04/1/2025 |
52 Weeks Range 2.67 - 17.31 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -0.18 | Actual -0.0981 |
Profitability
Profit Margin -58.71% | Operating Margin (TTM) -15.89% |
Management Effectiveness
Return on Assets (TTM) -7.64% | Return on Equity (TTM) -95.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 146522108 | Price to Sales(TTM) 3.1 |
Enterprise Value 146522108 | Price to Sales(TTM) 3.1 | ||
Enterprise Value to Revenue 2.74 | Enterprise Value to EBITDA -1.04 | Shares Outstanding 11790400 | Shares Floating 7816905 |
Shares Outstanding 11790400 | Shares Floating 7816905 | ||
Percent Insiders 20.93 | Percent Institutions 40.75 |
Analyst Ratings
Rating 5 | Target Price 11 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
LENSAR Inc
Company Overview
History and Background
LENSAR, Inc. designs, develops, and commercializes a femtosecond laser system for cataract surgery. Founded in 2004, the company has focused on improving the safety, accuracy, and efficiency of refractive cataract surgery.
Core Business Areas
- Cataract Surgery Systems: The primary business segment revolves around the LENSAR Laser System, used for femtosecond laser-assisted cataract surgery (FLACS).
Leadership and Structure
The leadership team consists of key executives overseeing various departments. The structure is typically hierarchical, with departments such as R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- LENSAR Laser System: The LENSAR Laser System is a femtosecond laser system designed for precision cataract surgery. It automates several manual steps, potentially improving accuracy and efficiency. It has a small but significant market share. Competitors include Alcon (ALC), Johnson & Johnson (JNJ), and Carl Zeiss Meditec (AFX.DE).
Market Dynamics
Industry Overview
The cataract surgery market is driven by an aging population and technological advancements. The adoption of femtosecond lasers continues to increase, although it's not universal due to cost and perceived benefits.
Positioning
LENSAR is positioned as an innovator in FLACS technology, focusing on advanced imaging and precision. It's a smaller player compared to larger companies with broader portfolios.
Total Addressable Market (TAM)
The TAM for cataract surgery is in the billions of dollars globally. LENSAR is targeting a specific segment of this market, FLACS. Its TAM is smaller but high margin.
Upturn SWOT Analysis
Strengths
- Advanced femtosecond laser technology
- Proprietary imaging system
- Focus on precision and accuracy
Weaknesses
- Limited market share compared to larger competitors
- High cost of the LENSAR Laser System
- Reliance on capital equipment sales
Opportunities
- Growing adoption of FLACS technology
- Expanding into new markets
- Developing new applications for femtosecond lasers in ophthalmology
Threats
- Competition from established players
- Price pressure from alternative technologies
- Regulatory hurdles for new products
Competitors and Market Share
Key Competitors
- Alcon (ALC)
- Johnson & Johnson (JNJ)
- Carl Zeiss Meditec (AFX.DE)
Competitive Landscape
LENSAR's advantage lies in its advanced technology. However, its smaller size and limited resources pose a disadvantage compared to larger, more established competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Requires private financial data to assess past growth.
Future Projections: Future projections are not publicly available for a private company.
Recent Initiatives: Recent initiatives would be private company information not accessible from public resources.
Summary
LENSAR Inc. has advanced femtosecond laser technology for cataract surgery, offering potential for improved accuracy and precision. Its smaller market share compared to industry giants necessitates a focus on innovation and strategic partnerships. Success depends on increasing adoption of FLACS technology and competing effectively with larger, well-established competitors. LENSAR must navigate regulatory hurdles and price competition to maintain its market position. Information provided is for informational purposes only and not investment advice, given LNSR is a private company.
Similar Companies
ALC
Alcon AG
ALC
Alcon AG
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Market Analysis
Disclaimers:
Data and analysis are based on available public information and may be limited due to LENSAR Inc.'s private status. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LENSAR Inc
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2020-10-02 | President, CEO & Director Mr. Nicholas T. Curtis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 140 | Website https://www.lensar.com |
Full time employees 140 | Website https://www.lensar.com | ||
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.